Latest Period
Q2 2026
Security Snapshot
Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share (VRXAW) Institutional Ownership
CUSIP: H9130A111
13F Institutional Holders and Ownership History for Q2 2026
Institutions Reporting
26
Shares (Excl. Options)
8,886,388
Price
$0.11
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Security type / class
- Equity / Ordinary Shares, par value CHF 100/11325 per share
- Symbol
- VRXAW on Nasdaq
- All holders as of 30 Jun 2026
- Q2 2026
- Total 13F shares
- 8,886,388
- Total 13F value
- $992,502
- Portfolio coverage rank
- 0%
- Share change
- +8,633,181
- Value change
- +$964,573
- Number of holders
- 26
- Shares outstanding
- 141,303,920
- SEC-reported price per share
- $0.08
Latest holder snapshot
5 signals
Issuer context
Names, identifiers, and filing context for this profile.
2 identity fields
13F Shares, Excluding Options vs Price
13F Value, Excluding Options
Total Investors
Key facts
- VRXAW - Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share is tracked under CUSIP H9130A111.
- 26 institutions reported positions in Q2 2026.
- 4 significant owners is listed from Schedule 13D/13G reporting.
Change
- Latest quarter on this page is Q2 2026.
- Additional quarter-over-quarter change detail appears as history expands.
Research use
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Evidence
Source: SEC Form 13F
Open SEC evidence
Latest holder context comes from 26 institutions filings for Q2 2026.
Security key
H9130A111
Latest holder period
Q2 2026
13F holders
26
13D/G owners
4
CIK / CUSIP context first
Open Q2 2026 holders
VRXAW full holder history
Veraxa Biotech Holding AG SEC filings
Veraxa Biotech Holding AG insider transactions
Broader feeds
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP H9130A111:
13D/G owners
Significant owners
Large-stake holder rows connected to Schedule 13D/G evidence.
Rows
4
Security
VRXAW
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Deck David Lukas | 18% | 25,502,836 | Deck David Lukas | 10 Jun 2026 | ||||
| Xlife Sciences AG | 16% | 23,029,967 | Xlife Sciences AG | 10 Jun 2026 | ||||
| European Molecular Biology Laboratory | 16% | 22,891,235 | European Molecular Biology Laboratory | 10 Jun 2026 | ||||
| Schoeni Gilbert Edgar | 16% | 22,539,749 | Schoeni Gilbert Edgar | 10 Jun 2026 |
As of 30 Jun 2026, 26 institutional investors reported holding 8,886,388 shares of Veraxa Biotech AG - Post de-SPAC - Ordinary Shares, par value CHF 100/11325 per share (VRXAW). This represents 6.3% of the company’s total 141,303,920 outstanding shares.
Quarter history
Institutional holders across reporting periods
Holder count, reported shares/value, and median price by quarter.
Periods
1
Latest
Q2 2026
Rows shown
1-1 of 1
| Period | 13F Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q2 | 8,886,388 | $992,502 | +$964,573 | $0.11 | 26 |